David Parrot insider trades: Scribe Therapeutics (SCTX) stock purchases
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where David reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jul 23, 2026 | SCTX | ↑ Buy | 1,333 | $15.00 | $20K | By Spouse | Jul 27, 2026 (4d) |
| Jul 23, 2026 | SCTX | ↑ Buy | 1,333 | $15.00 | $20K | By Child | Jul 27, 2026 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other SCTX insiders
Open-market trades in the last 12 months
About David Parrot's insider trades
David Parrot is Chief Financial Officer at Scribe Therapeutics (SCTX). Since Jul 23, 2026, David has reported 2 open-market purchases worth $40K and no sales on SEC Form 4. In the last 12 months: 2 buys ($40K).
Their filings also include grants and awards (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every SCTX insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.